|
|
Unconventional protocols in treatment of glioblastoma
Potomová, Petra ; Kubíková, Iva (advisor) ; Škvárová, Karolina (referee)
Glioblastoma multiforme is one of the tumours defying the treatment that is currently in use (radiotherapy and chemotherapy). Due to the failure in its complete repression, new methods were developed, methods that do not fulfil the traditional expectation about oncological treatment. But it's these methods that could lead to inhibition of further proliferation and growth of the tumour. Therapies, like anti-angiogenesis, ketogenic diet, photothermal therapy or ferroptosis, can be targeted against the tumour and significantly tip the oncological treatment in favour of patients and doctors. Despite the need to optimize them due to side effects, added toxicity or development of resistance, they play a vital role in the future of oncology. Keywords: glioblastoma multiforme, oncological treatment; anti-angiogenic therapy, ketogenic diet, photothermal therapy, ferroptosis
|
|
|
The role of WT1 and its isoforms in normal haematopoiesis and leukaemogenesis
Škvárová, Karolina
Wilms' tumor gene 1 (WT1) is highly expressed in acute leukemia and other hematological malignancies. It has been therefore suggested as a potential universal marker of minimal residual disease (MRD), particularly in patients with acute myeloid leukemia (AML). Due to controversial results of some of the studies, the role of WT1 in MRD follow- up and WT1 prognostic significance remain unclear. WT1 protein is produced in more than 36 different isoforms. These variants have distinct, partially overlapping functions and their ratio is supposed to influence the final effect of WT1. However, despite the increasing number of studies, the clinical impact of WT1 and its isoforms in acute leukemia have not yet been elucidated. We established a unique qPCR method to assess the expression pattern of the main 4 WT1 isoforms. Using this method, we determined the ratio of WT1 variants in the samples of patients with AML, myelodysplastic syndrome (MDS) and healthy controls. Our data showed that this pattern can distinguish among particular hematological malignancies, but lacks a prognostic significance. Within our international study group we determined the prognostic significance of total WT1 expression in childhood AML. Based on our results of a large cohort of patients we can conclude that WT1 expression at...
|
|
|
The role of WT1 and its isoforms in normal haematopoiesis and leukaemogenesis
Škvárová, Karolina
Wilms' tumor gene 1 (WT1) is highly expressed in acute leukemia and other hematological malignancies. It has been therefore suggested as a potential universal marker of minimal residual disease (MRD), particularly in patients with acute myeloid leukemia (AML). Due to controversial results of some of the studies, the role of WT1 in MRD follow- up and WT1 prognostic significance remain unclear. WT1 protein is produced in more than 36 different isoforms. These variants have distinct, partially overlapping functions and their ratio is supposed to influence the final effect of WT1. However, despite the increasing number of studies, the clinical impact of WT1 and its isoforms in acute leukemia have not yet been elucidated. We established a unique qPCR method to assess the expression pattern of the main 4 WT1 isoforms. Using this method, we determined the ratio of WT1 variants in the samples of patients with AML, myelodysplastic syndrome (MDS) and healthy controls. Our data showed that this pattern can distinguish among particular hematological malignancies, but lacks a prognostic significance. Within our international study group we determined the prognostic significance of total WT1 expression in childhood AML. Based on our results of a large cohort of patients we can conclude that WT1 expression at...
|
guest ::
RSS feed.